Eli Lilly's 340B Termination Turns Into Litigation and Congressional Pushback — Tampa General Sues in Federal Court, 72 House Members Demand HHS Act

Eli Lilly's June 1 five-day ultimatum escalated on June 18, 2026, when the manufacturer cut off 340B pricing for covered entities that refused to share in-house pharmacy claims data — Lilly directed wholesaler McKesson to end Tampa General Hospital's discounts after it missed the deadline, per the hospital's complaint. Tampa General sued Lilly on July 2 in the U.S. District Court for the Middle District of Florida, alleging the cutoff raised its average costs for Lilly medications 25-50% — losses the complaint pegs at roughly $24.7 million a year, including a 35.9% jump on Mounjaro. Separately, 72 bipartisan U.S. House members — led by Reps. Doris Matsui (D-CA) and Jack Bergman (R-MI) — signed an early-July letter to HHS Secretary Kennedy and HRSA Administrator Engels urging use of 'any enforcement mechanisms available' against Lilly's move and restoration of 340B pricing. Coverage so far documents hospitals as the entities cut off; no health-center termination has been confirmed, but FQHCs dispensing Lilly products face the same claims-data condition documented in the June 1 ultimatum item and should confirm their data-sharing posture now.

New Federal Data: ACA Marketplace Enrollment Fell to 19.2M — Down ~2.6M Year-Over-Year — After Enhanced Subsidies Expired; Ohio and Oklahoma Each Lost a Third of Enrollees

Federal effectuated-enrollment data posted in late June — analyzed in an ASPE issue brief (June 26) and reported state-by-state by the Associated Press on July 6 — shows about 19.2 million people had ACA Marketplace coverage in February 2026, roughly 2.6 million fewer than in February 2025, following the January 1 expiration of enhanced premium tax credits. Measured from 2025's 22.1 million peak, KFF puts the decline at 13% and notes average monthly premium payments jumped 58%; KFF projects enrollment could average roughly 17.5 million by the end of 2026. The state picture is stark: Ohio and Oklahoma each lost more than 32% of enrollees; Arizona, South Carolina, Minnesota, Indiana, Michigan, Mississippi, Louisiana, and Missouri each lost more than a quarter; Florida lost the largest raw number (~443,000). Only New Mexico gained enrollees (+14%) — the one state that fully replaced the lost federal subsidies with its own funds. HHS separately attributes 2.9 million of the enrollment reduction to program-integrity actions (a distinct measure, not the same 2.6M year-over-year figure). Every Marketplace dropout is a prospective uninsured sliding-fee patient — a durable uncompensated-care pressure signal for FQHCs nationwide through 2026.

DOJ Stands Up National Fraud Enforcement Division — Healthcare Billing Now Has a Dedicated Litigating Division

Acting U.S. Attorney General Todd Blanche announced (April 7, 2026) the National Fraud Enforcement Division (NFED) — a stand-alone DOJ litigating division consolidating the Tax Section, Health Care Fraud Unit, and Market/Government/Consumer Fraud Unit under one assistant attorney general. Each U.S. Attorney's office must designate a prosecutor to NFED within 21 days. A new National Fraud Detection Center generates investigative leads from federal financial data — meaning billing anomalies can trigger investigation independent of whistleblower complaints. Combined with FY2025 record $6.8B FCA recoveries (84% from healthcare = $5.7B), 2026 enforcement risk is structurally elevated for FQHCs. PPS billing, incident-to claims, telehealth FQHC distant-site billing, 340B claim integrity, and Anti-Kickback/Stark exposure are all in scope. Strategic action items for CFOs and compliance officers in May–June: (1) refresh PPS encounter documentation review, (2) audit incident-to billing for NP/PA visits, (3) reconfirm 340B contract pharmacy patient-definition compliance, (4) tighten BAA inventory and breach-response runbook (pairs with the OCR ransomware sweep enforcement posture).